Literature DB >> 2461962

In vitro proliferative responses and antibody titers specific to human acetylcholine receptor synthetic peptides in patients with myasthenia gravis and relation to HLA class II genes.

S Brocke1, C Brautbar, L Steinman, O Abramsky, J Rothbard, D Neumann, S Fuchs, E Mozes.   

Abstract

To investigate which parts of the acetylcholine receptor are involved in the initiation and development of myasthenia gravis (MG), peptides representing different sequences of the human acetylcholine receptor alpha-subunit were synthesized. These peptides were tested for their ability to stimulate T cells of myasthenic patients and healthy control patients in proliferation assays and to bind to sera antibodies. Three of eight peptides discriminated significantly between the two groups in the proliferation assay, as well as in their ability to bind to serum antibodies. HLA-DR3 and DR5 were associated with proliferative responses to specific AChR peptides in the group of myasthenics. Acetylcholine receptor epitopes that might play a specific role in myasthenia gravis thus were demonstrated.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2461962      PMCID: PMC442769          DOI: 10.1172/JCI113807

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  29 in total

1.  Serotyping for homotransplantation. 18. Refinement of microdroplet lymphocyte cytotoxicity test.

Authors:  K K Mittal; M R Mickey; D P Singal; P I Terasaki
Journal:  Transplantation       Date:  1968-11       Impact factor: 4.939

2.  In vivo therapy with monoclonal anti-I-A antibody suppresses immune responses to acetylcholine receptor.

Authors:  M K Waldor; S Sriram; H O McDevitt; L Steinman
Journal:  Proc Natl Acad Sci U S A       Date:  1983-05       Impact factor: 11.205

3.  Clinical, pathological, HLA antigen and immunological evidence for disease heterogeneity in myasthenia gravis.

Authors:  D A Compston; A Vincent; J Newsom-Davis; J R Batchelor
Journal:  Brain       Date:  1980-09       Impact factor: 13.501

4.  HLA-D typing in multiple sclerosis: Israelis tested with European homozygous typing cells.

Authors:  C Brautbar; A Amar; N Cohen; J Oksenberg; I Cohen; E Kahana; D Bloch; M Alter; H Grosse-Wilde
Journal:  Tissue Antigens       Date:  1982-03

Review 5.  Microdroplet testing for HLA-A, -B, -C, and -D antigens. The Phillip Levine Award Lecture.

Authors:  P I Terasaki; D Bernoco; M S Park; G Ozturk; Y Iwaki
Journal:  Am J Clin Pathol       Date:  1978-02       Impact factor: 2.493

6.  Significance in neonatal myasthenia gravis of inhibitory effect of amniotic fluid on binding of antibodies to acetylcholine receptor.

Authors:  O Abramsky; T Brenner; R P Lisak; A Zeidman; Y Beyth
Journal:  Lancet       Date:  1979 Dec 22-29       Impact factor: 79.321

7.  Cellular response to human acetylcholine receptor in patients with myasthenia gravis.

Authors:  D P McQuillen; S M Koethe; M P McQuillen
Journal:  J Neuroimmunol       Date:  1983-08       Impact factor: 3.478

8.  Immune response potential to poly(Tyr,Glu)-poly(DLAla)--poly(Lys) of human T cells of different donors.

Authors:  D Katz; Z Bentwich; N Eshhar; I Löwy; E Mozes
Journal:  Proc Natl Acad Sci U S A       Date:  1981-07       Impact factor: 11.205

9.  Anti-acetylcholine receptor antibodies in myasthenia gravis. Part 1. Relation to clinical parameters in 250 patients.

Authors:  P C Limburg; T H The; E Hummel-Tappel; H J Oosterhuis
Journal:  J Neurol Sci       Date:  1983-03       Impact factor: 3.181

10.  A sequence pattern common to T cell epitopes.

Authors:  J B Rothbard; W R Taylor
Journal:  EMBO J       Date:  1988-01       Impact factor: 11.598

View more
  39 in total

Review 1.  Current and future therapies for myasthenia gravis.

Authors:  Q Yi; A K Lefvert
Journal:  Drugs Aging       Date:  1997-08       Impact factor: 3.923

2.  Down-regulation of myasthenogenic T cell responses by a dual altered peptide ligand via CD4+CD25+-regulated events leading to apoptosis.

Authors:  Hava Ben-David; Michael Sela; Edna Mozes
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-26       Impact factor: 11.205

3.  A dual altered peptide ligand down-regulates myasthenogenic T cell responses and reverses experimental autoimmune myasthenia gravis via up-regulation of Fas-FasL-mediated apoptosis.

Authors:  Badiga Venkata Aruna; Hava Ben-David; Michael Sela; Edna Mozes
Journal:  Immunology       Date:  2006-07       Impact factor: 7.397

4.  Inhibition of T-cell reactivity to myasthenogenic epitopes of the human acetylcholine receptor by synthetic analogs.

Authors:  Y Katz-Levy; S L Kirshner; M Sela; E Mozes
Journal:  Proc Natl Acad Sci U S A       Date:  1993-08-01       Impact factor: 11.205

5.  The nature of the active suppression of responses associated with experimental autoimmune myasthenia gravis by a dual altered peptide ligand administered by different routes.

Authors:  M Paas-Rozner; M Sela; E Mozes
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-16       Impact factor: 11.205

6.  Presentation of endogenous acetylcholine receptor antigen to a specific CD4+ T-cell line by a transfected B-cell line.

Authors:  A F Mulcahy; D M Beeson; N Willcox; A G Diamond
Journal:  Immunology       Date:  1995-09       Impact factor: 7.397

Review 7.  Functional defect in regulatory T cells in myasthenia gravis.

Authors:  Muthusamy Thiruppathi; Julie Rowin; Qin Li Jiang; Jian Rong Sheng; Bellur S Prabhakar; Matthew N Meriggioli
Journal:  Ann N Y Acad Sci       Date:  2012-12       Impact factor: 5.691

8.  Altered peptide ligands act as partial agonists by inhibiting phospholipase C activity induced by myasthenogenic T cell epitopes.

Authors:  A Faber-Elmann; M Paas-Rozner; M Sela; E Mozes
Journal:  Proc Natl Acad Sci U S A       Date:  1998-11-24       Impact factor: 11.205

9.  Strategies for treating autoimmunity: novel insights from experimental myasthenia gravis.

Authors:  Matthew N Meriggioli; Jian Rong Sheng; Liangcheng Li; Bellur S Prabhakar
Journal:  Ann N Y Acad Sci       Date:  2008       Impact factor: 5.691

10.  Granulocyte macrophage colony-stimulating factor treatment of a patient in myasthenic crisis: effects on regulatory T cells.

Authors:  Julie Rowin; Muthusamy Thiruppathi; Ebinehita Arhebamen; Jianrong Sheng; Bellur S Prabhakar; Matthew N Meriggioli
Journal:  Muscle Nerve       Date:  2012-09       Impact factor: 3.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.